SRR12696795
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.600
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V2+0.500
- DNA_REPAIR+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- PANCREAS_BETA_CELLS+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- MTORC1_SIGNALING+0.300
- MITOTIC_SPINDLE+0.200
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- ANGIOGENESIS-0.500
- COAGULATION-0.500
- COMPLEMENT-0.500
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- APOPTOSIS-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YETBN0RQ | medulloblastoma | — | 0.940 |
| 2 | BS_M84H3KXA | medulloblastoma | — | 0.936 |
| 3 | BS_JTMXAMB7 | medulloblastoma | — | 0.935 |
| 4 | TCGA-44-7667-01A-31R-2066-07 | — | cohortA3 | 0.934 |
| 5 | BS_YBJBSRHV | Embryonal tumors | — | 0.932 |
| 6 | SRR10900570 | — | — | 0.930 |
| 7 | BS_HKZENFDA | medulloblastoma | — | 0.930 |
| 8 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.929 |
| 9 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.928 |
| 10 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |